The organisers regret that in the original publication of this abstract the Table: 925MO was incorrectly formatted. The correctly formatted table is now given here.
Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation”
Annals of Oncology | | M.B.B. Foote, J. Li, D.S. Tan, P.A. Calvo Ferrandiz, R. Galot, E. Garralda, T.K.K. Guren, A. Italiano, C.-C. Lin, Z.A.A. Wainberg, J. Yachnin, T.A. Yap, R. de Kanter, N. Grande, A. Izaac, D. Jankovic, L. Sansregret, C. Zhang, A.K. Nagaraja, Y. Kuboki
Topics: clinical-trials, new-technology, research